DEF: Oxbridge Re Holdings Sets Date for 2025 Annual General Meeting, Proposes Director Elections and Warrant Issuance Approval

Oxbridge Re Holdings Limited will hold its Annual General Meeting on May 8, 2025, to vote on director elections, auditor ratification, and approval for the issuance of ordinary shares upon warrant exercises.

Summary

• Oxbridge Re Holdings Limited will hold its Annual General Meeting of Shareholders on May 8, 2025, in Grand Cayman.
• Shareholders will vote on the election of five directors to serve until the 2026 Annual General Meeting.
• The meeting will also include a vote to ratify the appointment of Hacker, Johnson & Smith, P.A., as the company's independent auditors for the fiscal year ending December 31, 2025.
• A key proposal involves seeking shareholder approval for the issuance of more than 19.99% of outstanding ordinary shares upon the exercise of Series B warrants, combined with other securities issued in a recent transaction.
• The record date for determining shareholders eligible to vote is March 14, 2025.
• The company's Board of Directors recommends voting FOR all proposals.
• The company is asking stockholders to approve the issuance of more than 19.99% of our outstanding ordinary shares issuable upon the exercise of certain warrants issued pursuant to a Securities Purchase Agreement, dated February 24, 2025.
• On February 24, 2025, we and an institutional investor (the Purchaser) entered into the Purchase Agreement, pursuant to which we agreed to issue to the Purchaser an aggregate of 705,884 of our ordinary shares, Series A Warrants to purchase up to an aggregate of 529,413 ordinary shares (the Series A Warrants), and Series B Warrants to purchase up to an aggregate of 882,355 ordinary shares (the Series B Warrants and together with the Series A Warrants, the Warrants) (the Transaction).

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, outlining the agenda for the Annual General Meeting. While there are potential risks associated with share dilution, the overall tone is neutral and focused on seeking necessary approvals.

Positives

• The Board of Directors is actively engaged in corporate governance, with multiple committees overseeing key areas such as audit, compensation, and underwriting.
• The company has a Code of Business Conduct and Ethics and an Insider Trading Policy in place.
• A clawback policy is in effect for executive compensation recovery in the event of accounting restatements.
• The company is taking steps to ensure compliance with Nasdaq listing rules regarding shareholder approval for significant share issuances.

Negatives

• The issuance of shares upon exercise of the Warrants will have a dilutive effect on current stockholders.
• The percentage ownership of the company held by current stockholders will decline as a result of the issuance of the shares of ordinary shares underlying the Series B Warrants.
• Dilution of equity interests could also cause prevailing market prices for our ordinary shares to decline.
• If the Series B Warrants are exercised in full for cash, a total of 882,355 shares of ordinary shares will be issuable to the holders of the Series B Warrants and this dilutive effect may be material to current stockholders of the company.

Risks

• Failure to obtain shareholder approval for the warrant issuance could discourage future investors.
• The issuance of shares upon warrant exercise will dilute existing shareholders' ownership.
• Provisions in the warrants could discourage a third party from acquiring the company.
• There may be future sales of our ordinary shares, which could adversely affect the market price of our ordinary shares.

Future Outlook

The company intends to continue reviewing and modifying its compensation policies to attract, motivate, and retain highly skilled executives and employees to execute on its strategic objectives.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual shareholder meetings, addressing standard governance matters and seeking necessary approvals for strategic financial transactions.

Comparison to Industry Standards

• The director compensation structure, including cash fees and stock awards, is generally in line with industry practices for companies of similar size and complexity.
• The company's corporate governance practices, such as having independent directors and key committees, align with Nasdaq listing requirements and best practices.
• The proposal to approve the issuance of shares upon warrant exercise is a common scenario for companies seeking to raise capital, and the need for shareholder approval is dictated by Nasdaq rules.

Related Party Transactions

• Jay Madhu, a director and officer, purchased EpsilonCat Re tokens for $92,447, which indirectly confers interests in reinsurance contracts underwritten by Oxbridge Re NS.
• The company entered into a reinsurance agreement with TypTap, an insurance subsidiary of HCI Group, Inc., where Jay Madhu also serves as a director.
• The Company invested the sum of $100,000 in the Notes and is recorded as Loan Receivable on the consolidated balance sheets at cost.
• On March 11, 2024, the Notes matured and were redeemed by Jet.AI in accordance with the Bridge Agreement.
• The Company receive an aggregate of $140,000 upon the redemption of the Notes.
• Wrendon Timothy, our Chief Financial Officer, Corporate Secretary, and director serves on the board of directors of Jet.AI.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key decisions affecting the company's governance and capital structure.
• The outcome of the warrant issuance proposal will impact the ownership stake of existing shareholders.
• Employees are indirectly affected by the company's overall financial health and strategic direction.

Next Steps

• Shareholders are urged to review the proxy materials and vote on the proposals.
• The company will hold the Annual General Meeting on May 8, 2025.
• The company will continue to seek shareholder approval for the warrant issuance.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Director Election, Auditor Ratification, Warrant Issuance, Shareholder Approval, Corporate Governance, Oxbridge Re